A Single-Centre, Investigator/Subject Blind, Placebo-Controlled, Single and Multiple Oral Dose Investigation of Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Padsevonil (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors UCB Biopharma
- 17 Aug 2017 Status changed from recruiting to completed.
- 02 Jun 2017 Status changed from not yet recruiting to recruiting.
- 02 Jun 2017 New trial record